CP
Therapeutic Areas
Mirum Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LIVMARLI (maralixibat) | Alagille Syndrome (ALGS) | Approved |
| Brelovitug | Chronic Hepatitis Delta Virus (HDV) | Phase 3 |
| Volixibat | Primary Sclerosing Cholangitis (PSC) | Phase 2b |
Leadership Team at Mirum Pharmaceuticals
EB
Eric Bjerkholt
Chief Financial Officer
EC
Erin Campany
Chief People Officer
HJ
Hassan Javanbakht, Ph.D.
Chief Scientific Officer
JG
Jean-Luc Girardet, Ph.D.
Chief Technical Officer
VK
Vinita Kumar
Senior Vice President, Quality
LL
Lara Longpre
Chief Development Officer
JQ
Joanne Quan, M.D.
Chief Medical Officer
PR
Peter Radovich
President & Chief Operating Officer
DS
Doug Sheehy, JD
Chief Legal Officer
NS
Nancy Shulman, M.D.
Executive Vice President, Clinical